Vivanza Biosciences Limited

BSE:530057 Stock Report

Market Cap: ₹148.4m

Vivanza Biosciences Past Earnings Performance

Past criteria checks 2/6

Vivanza Biosciences has been growing earnings at an average annual rate of 42%, while the Medical Equipment industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 28.3% per year. Vivanza Biosciences's return on equity is 1.5%, and it has net margins of 0.4%.

Key information

42.0%

Earnings growth rate

40.8%

EPS growth rate

Medical Equipment Industry Growth23.0%
Revenue growth rate28.3%
Return on equity1.5%
Net Margin0.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Vivanza Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BSE:530057 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24164150
30 Jun 24211350
31 Mar 24279550
31 Dec 23317950
30 Sep 233101140
30 Jun 232501040
31 Mar 23182640
31 Dec 22160540
30 Sep 22114040
30 Jun 22129140
31 Mar 22112330
31 Dec 21112540
30 Sep 21105630
30 Jun 2199630
31 Mar 2199130
31 Dec 20130740
30 Sep 20120440
30 Jun 2098-230
31 Mar 2096-230
31 Dec 1950-830
30 Sep 1919-930
30 Jun 1921-820
31 Mar 1927-420
31 Dec 1825-210
30 Sep 1845100
30 Jun 1848200
31 Mar 1864210
31 Dec 1777320
30 Sep 1762030
30 Jun 1761-140
31 Mar 1735-340
31 Dec 169-540
30 Sep 165-330
30 Jun 160-210
31 Mar 160-100
31 Dec 150-100
30 Sep 150-100
30 Jun 150-100
31 Mar 150-100
31 Dec 140-100
30 Sep 140-100
30 Jun 140-100

Quality Earnings: 530057 has high quality earnings.

Growing Profit Margin: 530057's current net profit margins (0.4%) are lower than last year (3.6%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 530057 has become profitable over the past 5 years, growing earnings by 42% per year.

Accelerating Growth: 530057's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 530057 had negative earnings growth (-93.4%) over the past year, making it difficult to compare to the Medical Equipment industry average (8.8%).


Return on Equity

High ROE: 530057's Return on Equity (1.5%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 23:37
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vivanza Biosciences Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution